Abstract
Original language | English |
---|---|
Pages (from-to) | 123-130 |
Number of pages | 8 |
Journal | Crit. Rev. Oncol. Hematol. |
Volume | 137 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- Breast cancer risk
- Endometrial cancer risk
- Hormonal contraception
- Ovarian cancer risk
- contraceptive agent
- oral contraceptive agent
- breast cancer
- cancer risk
- climacterium
- endometrium cancer
- family history
- hormonal contraception
- human
- lifestyle modification
- obesity
- ovary cancer
- patient counseling
- Review
- risk reduction
- smoking
- breast tumor
- chemically induced
- counseling
- female
- healthy lifestyle
- procedures
- psychology
- risk
- Breast Neoplasms
- Contraceptives, Oral
- Contraceptives, Oral, Hormonal
- Counseling
- Female
- Healthy Lifestyle
- Humans
- Risk
Fingerprint Dive into the research topics of 'Breast cancer risk of hormonal contraception: Counselling considering new evidence: Critical Reviews in Oncology/Hematology'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Breast cancer risk of hormonal contraception: Counselling considering new evidence : Critical Reviews in Oncology/Hematology. / Del Pup, L.; Codacci-Pisanelli, G.; Peccatori, F.
In: Crit. Rev. Oncol. Hematol., Vol. 137, 2019, p. 123-130.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Breast cancer risk of hormonal contraception: Counselling considering new evidence
T2 - Critical Reviews in Oncology/Hematology
AU - Del Pup, L.
AU - Codacci-Pisanelli, G.
AU - Peccatori, F.
N1 - Cited By :3 Export Date: 26 February 2020 CODEN: CCRHE Correspondence Address: Codacci-Pisanelli, G.; Department of Medical and Surgical Sciences and Biotechnology, University “la Sapienza”Italy; email: giovanni.codacci-pisanelli@uniroma1.it Chemicals/CAS: Contraceptives, Oral; Contraceptives, Oral, Hormonal References: Backman, T., Rauramo, I., Jaakkola, K., Inki, P., Vaahtera, K., Launonen, A., Koskenvuo, M., Use of the levonorgestrel-releasing intrauterine system and breast cancer (2005) Obstet. Gynecol., 106, pp. 813-817; Bassuk, S.S., Manson, J.A.E., Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes (2015) Ann. Epidemiol., 25, pp. 193-200; Beaber, E.F., Malone, K.E., Tang, M.T.C., Barlow, W.E., Porter, P.L., Daling, J.R., Li, C.I., Oral contraceptives and breast cancer risk overall and by molecular subtype among young women (2014) Cancer Epidemiol. Biomark. Prev., 23, pp. 755-764; Brohet, R.M., Goldgar, D.E., Easton, D.F., Antoniou, A.C., Andrieu, N., Chang-Claude, J., Peock, S., Rookus, M.A., Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group (2007) J. Clin. Oncol., 25, pp. 3831-3836; Busund, M., Bugge, N.S., Braaten, T., Waaseth, M., Rylander, C., Lund, E., Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer study (2018) Int. J. Cancer, 142, pp. 2293-2302; Cavalieri, E., Rogan, E., The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity (2014) Mol. Asp. Med., 36, pp. 1-55; Chen, P., Li, M., Gu, X., Liu, Y., Li, X., Li, C., Wang, Y., Wang, H., Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies (2013) PLoS One, 8, p. e49312; Cibula, D., Gompel, A., Mueck, A.O., La Vecchia, C., Hannaford, P.C., Skouby, S.O., Zikan, M., Dusek, L., Hormonal contraception and risk of cancer (2010) Hum. Reprod. Update, 16, pp. 631-650; Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral, V., Doll, R., Hermon, C., Peto, R., Reeves, G., Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls (2008) Lancet, 371, pp. 303-314; Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies (1996) Lancet (Lond. Engl.), 347, pp. 1713-1727; de Sousa Almeida-Filho, B., De Luca Vespoli, H., Pessoa, E.C., Machado, M., Nahas-Neto, J., Nahas, E.A.P., Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women (2017) J. Steroid Biochem. Mol. Biol., 174, pp. 284-289; Del Pup, L., Becorpi, A., Breast cancer risk of hormonal contraception and hormone replacement therapy: how to counsel and reassure patients considering recent evidence (2018) Proceedings of the ISGE Congress; Del Pup, L., Berretta, M., Di Francia, R., Cavaliere, C., Di Napoli, M., Facchini, G., Fiorica, F., Schindler, A.E., Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk (2014) Anticancer Drugs, 25, pp. 745-750; Dinger, J., Bardenheuer, K., Do Minh, T., Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer (2011) Contraception, 83, pp. 211-217; Finlay-Schultz, J., Sartorius, C.A., Steroid hormones, steroid receptors, and breast cancer stem cells (2015) J. Mammary Gland Biol. Neoplasia, 20, pp. 39-50; Gierisch, J.M., Coeytaux, R.R., Urrutia, R.P., Havrilesky, L.J., Moorman, P.G., Lowery, W.J., Dinan, M., Myers, E.R., Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review (2013) Cancer Epidemiol. Biomark. Prev., 22, pp. 1931-1943; Grandi, G., Toss, A., Cagnacci, A., Marcheselli, L., Pavesi, S., Facchinetti, F., Cascinu, S., Cortesi, L., Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history (2017) Clin. Breast Cancer, 18, pp. e15-e24; Hannaford, P.C., Selvaraj, S., Elliott, A.M., Angus, V., Iversen, L., Lee, A.J., Cancer risk among users of oral contraceptives: cohort data from the royal college of general practitioners’ oral contraception study (2007) Br. Med. J., 335, pp. 651-654; Havrilesky, L.J., Moorman, P.G., Urrutia, R.P., Gierisch, J.M., Coeytaux, R.R., Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review (2013) Cancer Epidemiol., 22, pp. 1931-1943; Heikkinen, S., Koskenvuo, M., Malila, N., Sarkeala, T., Pukkala, E., Pitkäniemi, J., Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment (2016) Cancer Causes Control, 27, pp. 249-258; Hunter, D.J., Oral contraceptives and the small increased risk of breast cancer (2017) N. Engl. J. Med., 377, pp. 2276-2277; Hunter, D.J., Colditz, G.A., Hankinson, S.E., Malspeis, S., Spiegelman, D., Chen, W., Stampfer, M.J., Willett, W.C., Oral contraceptive use and breast cancer: a prospective study of young women (2010) Cancer Epidemiol. Biomark. Prev., 19, pp. 2496-2502; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy (2007) IARC Monogr. Eval. Carcinog. Risks Hum., 91, pp. 1-528; Iversen, L., Sivasubramaniam, S., Lee, A.J., Fielding, S., Hannaford, P.C., Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study (2017) Am. J. Obstet. Gynecol., 216, p. 580. , e1-580.e9; Kahlenborn, C., Modugno, F., Potter, D.M., Severs, W.B., Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis (2006) Mayo Clin. Proc., 81, pp. 1290-1302; Kim, Y., Je, Y., Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis (2014) Br. J. Cancer, 110, pp. 2772-2784; Li, L., Zhong, Y., Zhang, H., Yu, H., Huang, Y., Li, Z., Chen, G., Hua, X., Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis (2017) Mol. Clin. Oncol., 7, pp. 76-80; Lovett, J.L., Chima, M.A., Wexler, J.K., Arslanian, K.J., Friedman, A.B., Yousif, C.B., Strassmann, B.I., Oral contraceptives cause evolutionarily novel increases in hormone exposure (2017) Evol. Med. Publ. Health, 2017, pp. 97-108; Lyytinen, H.K., Dyba, T., Ylikorkala, O., Pukkala, E.I., A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well (2010) Int. J. Cancer, 126, pp. 483-489; Marchbanks, P.A., McDonald, J.A., Wilson, H.G., Folger, S.G., Mandel, M.G., Daling, J.R., Bernstein, L., Weiss, L.K., Oral contraceptives and the risk of breast cancer (2002) N. Engl. J. Med., 346, pp. 2025-2032; Morch, L.S., Skovlund, C.W., Hannaford, P.C., Iversen, L., Fielding, S., Lidegaard, Ø., Contemporary hormonal contraception and the risk of breast cancer (2017) N. Engl. J. Med., 377, pp. 2228-2239; Mueck, A.O., Seeger, H., Rabe, T., Hormonal contraception and risk of endometrial cancer: a systematic review (2010) Endocr. Relat. Cancer, 17, pp. 263-271; Peachman, R.R., Weighing the risks and benefits of hormonal contraception (2018) JAMA – J. Am. Med. Assoc., 319, pp. 1083-1084; Pierobon, M., Frankenfeld, C.L., Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis (2013) Breast Cancer Res. Treat., 137, pp. 307-314; Romieu, I., Willett, W.C., Colditz, G.A., Stampfer, M.J., Rosner, B., Hennekens, C.H., Speizer, F.E., Prospective study of oral contraceptive use and risk of breast cancer in women (1989) J. Natl. Cancer Inst., 81, pp. 1313-1321; Siegelmann-Danieli, N., Katzir, I., Landes, J.V., Segal, Y., Bachar, R., Rabinovich, H.R., Bialik, M., Lomnicky, Y., Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective (2018) Breast Cancer Res. Treat., 167, pp. 257-262; Sofi, N.Y., Jain, M., Kapil, U., Seenu, V., R, L., Yadav, C.P., Pandey, R.M., Sareen, N., Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: a case control study (2018) J. Steroid Biochem. Mol. Biol., 175, pp. 200-204; Soini, T., Hurskainen, R., Grénman, S., Mäenpää, J., Paavonen, J., Pukkala, E., Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland (2014) Obstet. Gynecol., 124, pp. 292-299; Tepper, N.K., Godfrey, E.M., Folger, S.G., Whiteman, M.K., Marchbanks, P.A., Curtis, K.M., Hormonal contraceptive use among women of older reproductive age: considering risks and benefits (2018) J. Women's Health, 27, pp. 413-417; Trummer, C., Pandis, M., Verheyen, N., Grübler, M.R., Gaksch, M., Obermayer-Pietsch, B., Tomaschitz, A., Schwetz, V., Beneficial effects of UV-radiation: vitamin D and beyond (2016) Int. J. Environ. Res. Publ. Health, 13, p. 1028; World Health Organization, Medical Eligibility Criteria for Contraceptive Use, Medical Eligibility Criteria for Contraceptive Use (2015), World Health Organization; Yin, L., Ordóñez-Mena, J.M., Chen, T., Schöttker, B., Arndt, V., Brenner, H., Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis (2013) Prev. Med., 57, pp. 753-764
PY - 2019
Y1 - 2019
N2 - The possibility that the use of hormonal contraceptives may increase the risk of breast cancer has been raised since many years. In the past this hypothesis has been dismissed on the basis that available data were generally derived from “old” studies in which relatively high hormone doses had been used. The recent publication of two studies that analysed data from women receiving low-dose hormonal contraception and showed a statistically significant increase in breast cancer contradicts this reassuring belief. The topic however is not settled, since different results were obtained in other studies and since hormonal contraception (HC) also has unquestionable positive effects such as a decrease in ovarian and in endometrial cancer. The aim of the present paper is to provide evidence that may help gynaecologists and oncologists in discussing with their patients the use of HC. Even if cancer phobia is a strong reason for not using or limiting HC, patients must be informed that notwithstanding the slightly increased breast cancer risk, the overall cancer risk may still be lower than non-users. Proper counselling may help the woman choose the most suitable contraception in the different phases of her life and on the basis of other conditions that may increase cancer risk such as overweight, smoking or family history. © 2019 Elsevier B.V.
AB - The possibility that the use of hormonal contraceptives may increase the risk of breast cancer has been raised since many years. In the past this hypothesis has been dismissed on the basis that available data were generally derived from “old” studies in which relatively high hormone doses had been used. The recent publication of two studies that analysed data from women receiving low-dose hormonal contraception and showed a statistically significant increase in breast cancer contradicts this reassuring belief. The topic however is not settled, since different results were obtained in other studies and since hormonal contraception (HC) also has unquestionable positive effects such as a decrease in ovarian and in endometrial cancer. The aim of the present paper is to provide evidence that may help gynaecologists and oncologists in discussing with their patients the use of HC. Even if cancer phobia is a strong reason for not using or limiting HC, patients must be informed that notwithstanding the slightly increased breast cancer risk, the overall cancer risk may still be lower than non-users. Proper counselling may help the woman choose the most suitable contraception in the different phases of her life and on the basis of other conditions that may increase cancer risk such as overweight, smoking or family history. © 2019 Elsevier B.V.
KW - Breast cancer risk
KW - Endometrial cancer risk
KW - Hormonal contraception
KW - Ovarian cancer risk
KW - contraceptive agent
KW - oral contraceptive agent
KW - breast cancer
KW - cancer risk
KW - climacterium
KW - endometrium cancer
KW - family history
KW - hormonal contraception
KW - human
KW - lifestyle modification
KW - obesity
KW - ovary cancer
KW - patient counseling
KW - Review
KW - risk reduction
KW - smoking
KW - breast tumor
KW - chemically induced
KW - counseling
KW - female
KW - healthy lifestyle
KW - procedures
KW - psychology
KW - risk
KW - Breast Neoplasms
KW - Contraceptives, Oral
KW - Contraceptives, Oral, Hormonal
KW - Counseling
KW - Female
KW - Healthy Lifestyle
KW - Humans
KW - Risk
U2 - 10.1016/j.critrevonc.2019.03.001
DO - 10.1016/j.critrevonc.2019.03.001
M3 - Article
VL - 137
SP - 123
EP - 130
JO - Crit. Rev. Oncol. Hematol.
JF - Crit. Rev. Oncol. Hematol.
SN - 1879-0461
ER -